Tenderwize
Retour à la recherche

Open-House contract for Bimatoprost/Timolol eye drops

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 29, 2026 · 125 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2024-14 - Bimatoprost / Timolol (Darreichungsform: Augentropfen als Einzeldosispipetten)

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

The notice says offers/contracts cannot be submitted through the procurement portal and must instead be sent by email w...

Participation is limited to pharmaceutical undertakings meeting AMG seat and authorisation requirements for the specifi...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of pharmaceutical rebate contracts under Section 130a(8) SGB V for Bimatoprost/Timolol eye drops in single-dose pipettes.
  • Open-House model with uniform terms; no individual contract negotiations.
Afficher le résumé complet

This is a German Open-House pharmaceutical supply arrangement for Bimatoprost/Timolol eye drops in single-dose pipettes, led by Techniker Krankenkasse with HEK as a participating buyer. It is not a classic award procedure: no individual negotiations, no exclusivity, and contract entry is possible throughout the contract period if eligibility conditions are met. The notice and XML indicate electronic submission via the portal is not allowed; contracts must be submitted by email with qualified electronic signature or by post. No contract value is stated.

Risques

The notice says offers/contracts cannot be submitted through the procurement portal and must instead be sent by email w...

Participation is limited to pharmaceutical undertakings meeting AMG seat and authorisation requirements for the specifi...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Bidder must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Bidder must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Bidder must hold a valid marketing authorisation for the contract medicinal product(s) or otherwise be entitled to place them on the market in its own name.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House contract for Bimatoprost/Timolol eye drops

Open-House pharmaceutical rebate contract for the fixed medicinal product combination Bimatoprost/Timolol in the form of single-dose eye drops. Scope is nationwide in Germany and the arrangement is open to all suitable pharmaceutical companies meeting the stated conditions. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Dec 2024 - Dec 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 29, 2026

Détails de la procédure

Date de publication
17 Nov 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
702294-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3